A diabetes sensor pulled 400 points and 198 comments on Hacker News by the time this story's brief was captured, unusual attention for a medical-device authorization. The interest makes sense from a systems perspective: Abbott's Libre Duo 10 Day turns ketone testing from an occasional snapshot into a second, minute-by-minute data stream beside glucose. The US Food and Drug Administration authorized the device on August 25 for people with diabetes aged two and older.
The authorization creates a new device category in the United States. According to the FDA, Libre Duo is the country's first wearable that continuously monitors ketones and the first single wearable anywhere to monitor both ketones and glucose continuously. Those carefully worded firsts matter. Blood meters that test both substances have existed for years; what has changed is the frequency and continuity of the ketone reading.
That change addresses a blind spot in current diabetes monitoring. Continuous glucose monitors produce a curve that shows direction and rate of change. Ketone tests have generally required a separate blood or urine sample and returned one value. A single reading cannot show whether ketones are climbing, holding steady, or dropping after someone takes action. The FDA says Libre Duo measures both substances in the fluid beneath the skin every minute and sends the readings wirelessly to a compatible smartphone.
Why the second curve matters
Ketones appear when the body burns fat for energy. In a person with diabetes, too little insulin can allow ketones to accumulate and lead to diabetic ketoacidosis, or DKA, which can become life-threatening quickly. The FDA describes the device's job in deliberately limited terms: it can alert users when ketones reach a concerning threshold, giving patients or caregivers an earlier signal that levels are rising. The agency also says ketone data should be interpreted with glucose readings and symptoms.
The combined display is more useful than adding another number to a health app. Glucose and ketones do not always move together. Abbott's European announcement for Libre Duo says ketones may rise even when glucose appears to be within range. This can happen in situations including illness and with some glucose-lowering medicines. A glucose-only alarm can therefore miss part of the developing problem.
A research protocol involving Abbott's dual sensor spells out the hardware idea. The ClinicalTrials.gov protocol describes two working electrodes in one under-skin electrochemical sensor, one for glucose and one for beta-hydroxybutyrate, the ketone measured by the system. A phone app activates the research sensor, logs both readings, and receives them over Bluetooth or another wireless connection. That protocol predates authorization and is research documentation, so its measurement ranges and study rules should not be treated as the final US consumer label. It does, however, show how two chemical channels fit into one wearable.
For users, the central output is a time series. A threshold alert can say that a value has crossed a line; the preceding readings show how it got there. The FDA says Libre Duo displays current values and whether each is trending up or down. That history may give a caregiver more useful information than an isolated test performed after symptoms appear, while the agency stops short of saying the device can diagnose DKA by itself.
What the FDA actually authorized
Libre Duo 10 Day is cleared for up to ten days of wear. The FDA based its decision on six clinical studies with more than 600 participants aged two and older, covering a range of glucose and ketone levels. The agency says the system tracked clinically meaningful differences in ketone levels over the wear period and identified elevated levels before DKA began. The public announcement does not provide the detailed accuracy tables, subgroup results, or false-alert rates that clinicians and device researchers will want to inspect.
The route to market was De Novo review, which the FDA uses for a new type of low-to-moderate-risk device without an existing predicate. That distinction explains why this is more than another Libre model with a software option enabled. The authorization establishes a classification and special controls for later devices of the same type, including requirements around labeling and performance testing. Future competitors may be able to use that regulatory foundation rather than starting with an entirely new category.
Before the De Novo decision, the FDA had given Libre Duo its Breakthrough Device designation. That designation is intended to speed development and review for technologies aimed at life-threatening or irreversibly debilitating conditions; it is not a substitute for marketing authorization. The completed De Novo review is the event that allows Abbott to market the device in the United States under the authorized conditions.
There are still limits visible in the FDA's own wording. The system provides readings and alerts, while people must consider symptoms and glucose at the same time. The announcement does not say that a ketone alert should directly change an insulin dose, nor does it announce autonomous treatment based on the second sensor channel. In a safety-sensitive loop, measuring another analyte and deciding what to do with it are separate engineering and clinical problems.
One sensor, several data paths
Abbott had already received a CE Mark in May for two versions of the technology. Its European release describes a 15-day Libre Duo for adults and the 10-day model for people aged two and older. The company said it planned launches in selected European countries later in 2026. The US authorization covers the Libre Duo 10 Day; the FDA announcement gives no retail date, price, phone compatibility list, or insurance details.
The company says the sensors connect to its Libre digital-health system so users can share glucose and ketone data with caregivers and health professionals. Abbott also says it is working with insulin-pump companies on connections to automated insulin-delivery systems. That is a design goal, according to the company, rather than an FDA-approved claim that ketone readings currently control a pump. Any such integration would need clear rules for delayed interstitial readings, missing data, sensor errors, and alert fatigue.
The data-sharing piece could change remote care before pump control changes. A clinician reviewing glucose now sees food, activity, and insulin reflected in one curve. Adding ketones can supply context when a person is ill, has missed insulin, or is at risk of DKA. Yet more frequent measurement also creates more alerts and more ambiguous edge cases. The FDA's insistence on reading the two values with symptoms is a reminder that a denser signal does not remove the need for judgment.
Researchers are already studying how continuous ketone data might support treatment rules. One registered clinical study of people with type 1 diabetes and chronic kidney disease uses Abbott's combined monitor while evaluating a DKA risk-reduction strategy around an SGLT inhibitor. Its stated goals include learning which factors predict ketosis and how participants and clinicians use combined reports. The existence of the study should not be read as proof that the strategy works; it shows that thresholds and responses remain active research questions.
That distinction will shape the product's next phase. The sensor can collect a ketone value every minute, but a useful alert policy needs to decide how high, how fast, and for how long a rise should persist before interrupting someone. Age, medication, illness, exercise, and food can affect the meaning of the curve. The research protocol explicitly asks whether one set of thresholds can work for everyone or whether advice should be individualized.
The first things to watch are concrete: Abbott's US availability and pricing, the authorized labeling and accuracy tables, the compatible-phone list, and any separately reviewed pump connections. After devices reach users, false alerts, ten-day completion rates, and evidence that earlier warnings change DKA outcomes will matter more than the novelty of putting two electrodes under one patch. The FDA has authorized the measurement system. How reliably people and software act on its second curve is the question that comes next.